• By ICR Secretariat
  • Posted Tuesday, July 9, 2019

Pressing the pause button on CAR-T cells with Bristol-Myers' leukemia drug


CAR-T cell therapies that transform a patient’s own immune cells into cancer-killing weapons have been hailed as breakthroughs for treating some blood cancers. But managing cytokine release syndrome (CRS), the most common acute side effect associated with CAR-T cells, is still a challenge. A team of researchers in Germany has now found a possible solution in Bristol-Myers Squibb’s leukemia drug Sprycel.